Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2021
October 26, 2021 at 04:15 am EDT
Share
Zhejiang Jolly Pharmaceutical Co.,LTD reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 1,078.47 million compared to CNY 769.55 million a year ago. Revenue was CNY 1,078.47 million compared to CNY 769.55 million a year ago. Net income was CNY 131.52 million compared to CNY 62.37 million a year ago. Basic earnings per share from continuing operations was CNY 0.2161 compared to CNY 0.1025 a year ago. Diluted earnings per share from continuing operations was CNY 0.2161 compared to CNY 0.1025 a year ago.
Zhejiang Jolly Pharmaceutical Co., Ltd. is a China-based company principally engaged in research, development, manufacture and sales of medicinal fungi series products. The Companyâs main business is mainly involved in pharmaceutical manufacturing, among which the activities are involved in manufacture and sale of active pharmaceutical ingredients, tablets, capsules, granules, Lyophilized powders and other products. The main products include Wuling series, bailing tablets series and Chinese medicine drinking tablets series, among others. Through its subsidiaries, the Company is also engaged in pharmaceutical circulation.